Rajni Agarwal

Dr. Rajni Agarwal

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 October 2021 in Science Translational Medicine
Verified
Journal Article
Closed access
PCPauline P. Chen
Pauline P. Chen
ACAlma-Martina Cepika
Alma-Martina Cepika
RARajni Agarwal
Rajni Agarwal
GSGopin Saini
Gopin Saini
MUMolly J. Uyeda
Molly J. Uyeda
MRMaria Grazia Roncarolo
Maria Grazia Roncarolo
Type 1 regulatory T cells suppress alloreactive immune cells after adoptive transfer in a CTLA-4 and PD-1–mediated manner.

1 February 2015 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
PGPhillip M. Garfin
Phillip M. Garfin
MLMichael P. Link
Michael P. Link
SDSarah S. Donaldson
Sarah S. Donaldson
RARanjana H. Advani
Ranjana H. Advani
SLSandra Luna-Fineman
Sandra Luna-Fineman
RARajni Agarwal
Rajni Agarwal
The purpose of this study is to evaluate the survival of pediatric patients undergoing autologous bone marrow transplantation (auBMT) for relapsed or refractory Hodgkin lymphoma (rrHL) and to identify factors that might contribute to their outcome. We reviewed the records and clinical course of 89 consecutive rrHL patients ≤ 21 years old who underwent auBMT at Stanford Hospitals and Clinics and the Lucile Packard Children's Hospital, Stanford between 1989 and 2012. We investigated, by multiple analyses, patient, disease, and treatment characteristics associated with outcome. Endpoints were 5-year overall and event-free survival. Our findings include that cyclophosphamide, carmustine, and etoposide (CBV) as a conditioning regimen for auBMT is effective for most patients ≤ 21 years old with rrHL (5-year overall survival, 71%). Transplantation after the year 2001 was associated with significantly improved overall survival compared with our earlier experience (80% compared with 65%). Patients with multiply relapsed disease or with disease not responsive to initial therapy fared less well compared with those with response to initial therapy or after first relapse. Administration of post-auBMT consolidative radiotherapy (cRT) also appears to contribute to improved survival. We are able to conclude that high-dose chemotherapy with CBV followed by auBMT is effective for the treatment of rrHL in children and adolescents. Survival for patients who undergo auBMT for rrHL has improved significantly. This improvement may be because of patient selection and improvements in utilization of radiotherapy rather than improvements in chemotherapy. Further investigation is needed to describe the role of auBMT across the entire spectrum of patients with rrHL and to identify the most appropriate preparative regimen with or without cRT therapy in the treatment of rrHL in young patients.

21 November 2014 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
BMBryan Mitton
Bryan Mitton
SCSteven Coutre
Steven Coutre
JWJennifer Willert
Jennifer Willert
KSKrysta Schlis
Krysta Schlis
MPMatthew Porteus
Matthew Porteus
RARajni Agarwal
Rajni Agarwal

1 January 2021 in Placenta
Verified
Journal Article
Open access
SMSruthi Mantri
Sruthi Mantri
ASAdam Sheikali
Adam Sheikali
CBCorey Binns
Corey Binns
DLDeirdre J. Lyell
Deirdre J. Lyell
DDDavid L. DiGiusto
David L. DiGiusto
RARajni Agarwal
Rajni Agarwal
Umbilical cord blood is an important graft source in the treatment of many genetic, hematologic, and immunologic disorders by hematopoietic stem cell transplantation. Millions of cord blood units have been collected and stored for clinical use since the inception of cord blood banking in 1989. However, the use of cord blood in biomedical research has been limited by access to viable samples. Here, we present a cost-effective, self-sustaining model for the procurement of fresh umbilical cord blood components for research purposes within hospital-affiliated academic institutions.

Verified
Journal Article
Open access
PDF file
SLSteven Levitte
Steven Levitte
AGAbantika Ganguly
Abantika Ganguly
SFSophie Frolik
Sophie Frolik
AGAlix A. Guevara-Tique
Alix A. Guevara-Tique
SPShaini Patel
Shaini Patel
Avnesh ThakorAvnesh Thakor
Avnesh Thakor
Graft versus host disease (GVHD) is one of the most serious complications following stem cell transplant in children and is a major cause of morbidity and mortality. Corticosteroids remain the mainstay of treatment, and although a majority of children respond to systemic steroids, those refractory to or dependent upon corticosteroids suffer from complications secondary to long-term steroid administration. This problem has prompted consideration of steroid-sparing treatment strategies, although the time to clinical remission can be variable. Intraarterial corticosteroid delivery has been used in adults as a rescue therapy in steroid-resistant patients, but its use in children has been limited. We investigated the feasibility of intraarterial steroid administration into the bowel and/or liver in a cohort of six pediatric patients with acute GVHD. All patients successfully underwent treatment with no serious adverse effects. Five of five (100%) patients with gastrointestinal bleeding due to GVHD had rapid symptom improvement by 48 h, which was durable up to three weeks. Three of four (75%) patients with hepatic GVHD had improved cholestasis following intraarterial steroid administration. Our experience with this small cohort preliminarily demonstrated the feasibility and safety of intraarterial steroid administration in children with acute GVHD. This approach warrants consideration as a rescue therapy in steroid-refractory cases and as a “bridge” therapy for children with severe acute GVHD who are transitioning to steroid-sparing regimens.

Verified
Journal Article
Open access
PDF file
DSDavid Shyr
David Shyr
SCSteven M. Chirieleison
Steven M. Chirieleison
SFSebastian Fernandez-Pol
Sebastian Fernandez-Pol
KWKatja G. Weinacht
Katja G. Weinacht
RARajni Agarwal
Rajni Agarwal
ABAlice Bertaina
Alice Bertaina
Background: Acute graft-versus-host disease (aGVHD) is a leading cause of morbidity and mortality following pediatric hematopoietic stem cell transplantation (HSCT). Approximately half of children achieve complete response (CR) to corticosteroids, whereas steroid-refractory (SR) disease carries a 1–2-year mortality of 41–44%. Mortality risk is 2.6-fold higher in children > 13.9 years, and respiratory failure accounts for 26% of deaths. Existing second-line agents—ruxolitinib, tocilizumab, or extracorporeal photopheresis—have delayed onset or high toxicity. Begelomab (BEGESAND®), a monoclonal antibody targeting CD26/dipeptidyl peptidase-4 (DPP4), inhibits CD26-mediated T-cell activation and has demonstrated 75% response in adults with minimal toxicity. However, pediatric data are lacking. Methods: We retrospectively reviewed five consecutive pediatric patients (ages 3–20 years) treated with Begelomab (BEGESAND®) for SR (n = 4) or steroid-dependent (SD; n = 1) aGVHD between 2017–2021 under emergency IND authorization. Begelomab (BEGESAND®) was administered intravenously at 2.7 mg/m2/day on days 1–5, 10, 14, 17, 21, 24, and 28. GVHD was graded by MAGIC criteria; flow cytometry and immunohistochemistry (IHC) assessed CD26 expression and immune effects. Results: All patients had grade IV disease after ≥2 prior agents. Two with pre-existing sepsis died early, before treatment response could be assessed. Of three evaluable patients, two (67%) achieved CR within 21 days and one achieved durable control by 6 months. All three remain alive; no Begelomab (BEGESAND®)-related toxicity, cytopenia, or new infections occurred. Flow cytometry showed preserved T-cell subsets, and IHC demonstrated CD26 localization at sites of epithelial injury. Conclusions: Begelomab (BEGESAND®) showed promising timely and durable responses with excellent safety in pediatric SR/SD-aGVHD, supporting further evaluation in multicenter pediatric trials.